生物製药CMO/CRO市场规模、份额和成长分析（按供应来源、服务类型、产品和地区划分）－产业预测（2026-2033年）

全球生物製药 CMO/CRO 市场预计到 2024 年将达到 343.1 亿美元，从 2025 年的 363.4 亿美元增长到 2033 年的 574.8 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.9%。

受消费者对创新治疗方法需求不断增长的推动，生物製药产业正经历显着成长。契约製造组织 (CMO) 和受託研究机构(CRO) 在支援製药公司方面发挥关键作用，前者透过外包生产运营，后者则提供全面的研究服务。这一趋势凸显了资源密集型流程（包括整个生物製造流程）外包的趋势，并推动了对合约服务的需求。透过併购整合生物製程能力，使 CMO 能够提供精简的解决方案，从而加速产品上市。对一体化生产的投资进一步加强了该行业，旨在提高生产力和效率的策略联盟便是明证。总体而言，CMO 和 CRO 在生物製药行业中扮演关键角色，占据了全球製药市场 20% 以上的份额。

生物製药CMO/CRO市场驱动因素

生物製药产业正经历一场旨在增强竞争力并拓展契约製造和服务业务的整合浪潮。随着新型治疗方法和创新生物工艺技术的涌现，合约生物生产公司面临着适应不断变化的市场动态的压力。为了满足相关人员和消费者多样化的需求，替代性经营模式正变得越来越普遍。此外，生产设施中一次性使用系统的应用预计将显着提高产能。这些因素共同为生物製药CMO和CRO市场带来了强劲的成长潜力，并在全球市场格局中创造了新的机会。

生物製药CMO/CRO市场面临的限制

儘管生物製药CMO/CRO市场相比製药CMO产业利润率更高，但其成长潜力仍面临许多限制因素。其中一个关键挑战是需要对生产设施和先进设备进行大量投资，以加速生物製药流程。此外，许多成熟的生物製药公司不愿完全采用外包模式，这进一步限制了市场扩张。另外，由于法规环境复杂且服务本身也较为复杂，CMO与客户之间的谈判也可能充满挑战。智慧财产权、保密性和担保等问题增加了客户与CMO签订合约的难度，进一步阻碍了市场成长。

生物製药CMO/CRO市场趋势

生物製药CMO/CRO市场呈现显着上升趋势，这主要得益于企业对新产品开发的日益重视、研发活动的持续拓展以及策略联盟的建立。随着企业面临研发效率下降和研发成本上升的挑战，CMO/CRO正成为加速产品商业化的关键合作伙伴。地域扩张、併购以及强化分销网络等成长策略对于企业获取竞争优势至关重要。这种不断变化的市场格局促使生物製药企业更加依赖合约组织，从而为生物製药行业的持续市场成长和创新铺平了道路。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术进步

全球生物製药CMO/CRO市场规模（依供应来源划分）、复合年增长率（2026-2033年）

• 哺乳动物起源
• 非哺乳动物起源

全球生物製药CMO/CRO市场依服务类型划分，复合年增长率（2026-2033年）

• 契约製造
  • 製程开发
  • 下游工艺
  • 上游工程
  • 填充和表面处理工程
  • 分析和品管测试
  • 包装
• 合约研究
  • 肿瘤学
  • 发炎/免疫学
  • 循环系统
  • 神经科学
  • 其他的

全球生物製药CMO/CRO市场规模（依产品划分），复合年增长率（2026-2033年）

• 生物製药
  • 单株抗体（MAbs）
  • 重组蛋白
  • 疫苗
  • 反义寡核苷酸、RNA干扰与分子疗法
  • 其他的
• 生物相似药

全球生物製药CMO/CRO市场规模及复合年增长率（2026-2033年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Lonza Group（Switzerland）
• Thermo Fisher Scientific（United States）
• Catalent（United States）
• WuXi Biologics（China）
• Samsung Biologics（South Korea）
• IQVIA（United States）
• Syneos Health（United States）
• ICON Plc（Ireland）
• Medpace Holdings（United States）
• Charles River Laboratories（United States）
• PPD（United States）
• Labcorp Drug Development（United States）
• Parexel International（United States）
• PRA Health Sciences（United States）
• BioNTech SE（Germany）
• Moderna, Inc.（United States）
• Gilead Sciences（United States）
• Regeneron Pharmaceuticals（United States）
• Vertex Pharmaceuticals（United States）
• Amgen Inc.（United States）

结论与建议

Biopharmaceutical CMO & CRO Market size was valued at USD 34.31 Billion in 2024 and is poised to grow from USD 36.34 Billion in 2025 to USD 57.48 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The biopharmaceutical industry is witnessing significant growth, driven by increasing consumer demand for innovative therapies. Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) have become pivotal in supporting pharmaceutical companies by providing outsourced manufacturing and comprehensive research services, respectively. This trend highlights a shift toward outsourcing resource-intensive processes, including entire biomanufacturing chains, enhancing the demand for contract-based services. The integration of bioprocessing capabilities through mergers and acquisitions allows CMOs to offer streamlined solutions, facilitating accelerated product launches. Investments in integrated manufacturing further bolster this sector, as evidenced by strategic partnerships aimed at improving productivity and efficiency. Overall, CMOs and CROs play a crucial role in the biopharmaceutical landscape, representing over 20% of the pharmaceutical market globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biopharmaceutical CMO & CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biopharmaceutical CMO & CRO Market Segments Analysis

Global Biopharmaceutical CMO and CRO Market is segmented by Source, Service Type, Product and region. Based on Source, the market is segmented into Mammalian and Non-mammalian. Based on Service Type, the market is segmented into Contract Manufacturing and Contract Research. Based on Product, the market is segmented into Biologics and Biosimilars. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biopharmaceutical CMO & CRO Market

The biopharmaceutical industry has experienced a wave of consolidations aimed at enhancing competitiveness and expanding operations within the contract manufacturing and service sectors. As new therapies and innovative bioprocessing techniques emerge, contract bioproducers face mounting pressures to adapt to these changes in market dynamics. To address the diverse needs of stakeholders and consumers, alternative business models are becoming more prevalent. Additionally, the implementation of single-use systems in manufacturing facilities is expected to significantly enhance production capacity. Collectively, these factors indicate strong growth potential for the biopharmaceutical CMO and CRO market, offering new opportunities in the global landscape.

Restraints in the Biopharmaceutical CMO & CRO Market

The biopharmaceutical CMO and CRO market faces several constraints that hinder its growth potential, despite the lucrative profit margins it offers compared to the pharmaceutical CMO sector. A primary challenge lies in the significant investments required for manufacturing facilities and advanced equipment to accelerate biomanufacturing processes. Additionally, many established biopharmaceutical companies are hesitant to fully embrace outsourcing, further limiting market expansion. Moreover, negotiations between CMOs and clients can be complicated due to the intricate regulatory environment and the complexity inherent in these services. Issues surrounding intellectual property rights, confidentiality, and warranties add to the difficulties in client-CMO agreements, creating further barriers to market growth.

Market Trends of the Biopharmaceutical CMO & CRO Market

The biopharmaceutical CMO and CRO market is experiencing a significant upward trend driven by an intensified focus on new product development, expanded R&D activities, and strategic collaborations. As companies face challenges in R&D efficiency and escalating development costs, CMOs and CROs are emerging as pivotal partners, facilitating faster commercial operations. Growth strategies such as geographical expansions, mergers and acquisitions, and enhanced distribution networks are becoming integral to gaining competitive advantages. This evolving landscape underscores the increasing reliance on contract organizations by biopharmaceutical firms, paving the way for sustained market growth and innovation in the biopharmaceutical sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement

Global Biopharmaceutical CMO & CRO Market Size by Source & CAGR (2026-2033)

• Market Overview
• Mammalian
• Non-mammalian

Global Biopharmaceutical CMO & CRO Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Contract Manufacturing
  • Process Development
  • Downstream
  • Upstream
  • Fill & Finish Operations
  • Analytical & QC Studies
  • Packaging
• Contract Research
  • Oncology
  • Inflammation & Immunology
  • Cardiology
  • Neuroscience
  • Others

Global Biopharmaceutical CMO & CRO Market Size by Product & CAGR (2026-2033)

• Market Overview
• Biologics
  • Monoclonal antibodies (MAbs)
  • Recombinant Proteins
  • Vaccines
  • Antisense, RNAi, & Molecular Therapy
  • Others
• Biosimilars

Global Biopharmaceutical CMO & CRO Market Size & CAGR (2026-2033)

• North America (Source, Service Type, Product)
  • US
  • Canada
• Europe (Source, Service Type, Product)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Source, Service Type, Product)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Source, Service Type, Product)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Source, Service Type, Product)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace Holdings (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PRA Health Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations